Frailty Prevalence >8 Percent in Young Adult HCT Survivors

This article originally appeared here.
Share this content:
Frailty Prevalence >8 Percent in Young Adult HCT Survivors
Frailty Prevalence >8 Percent in Young Adult HCT Survivors

TUESDAY, June 7, 2016 (HealthDay News) -- Among young adult hematopoietic cell transplantation (HCT) survivors, the prevalence of frailty exceeds 8 percent and is associated with increased risk of mortality, according to a study published online June 2 in JAMA Oncology.

Mukta Arora, M.D., from the University of Minnesota in Minneapolis, and colleagues determined the prevalence of frailty in young adult HCT patients and siblings in a cohort study. Data were included for 998 HCT survivors who underwent transplant procedures between 1974 and 1998 and 297 frequency-matched siblings.

The researchers found that among young adult HCT patients the prevalence of frailty exceeded 8 percent. Compared with their siblings, HCT survivors were 8.4 times more likely to be frail (P = 0.003). Among HCT recipients, the risk of frailty was increased for allogeneic HCT recipients with chronic graft-versus-host disease (GvHD) or resolved chronic GvHD compared with autologous HCT (odds ratios, 15.02 and 2.7, respectively). For HCT recipients with and without frailty, the cumulative incidence of subsequent all-cause mortality was 39.3 and 14.7 percent, respectively, at 10 years (P < 0.001). After adjustment for relevant prognosticators, frailty correlated with a 2.76-fold increased risk of subsequent mortality (P < 0.001).

"The prevalence of frailty among young-adult HCT survivors approaches that seen in the elderly general population," the authors write. "This study identifies vulnerable populations needing close monitoring to anticipate and manage morbidity and prevent mortality."

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »